Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
0 hedge funds and large institutions have $0 invested in Anebulo Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 18 closing their positions.
54.06% less ownership
Funds ownership: 54.06% → 0% (-54%)
100% less funds holding
Funds holding: 19 → 0 (-19)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $91.6M → $0 (-$91.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 18
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
-$84.8M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.07M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.55M |
| 4 |
Morgan Stanley
New York
|
-$403K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$162K |
ANEB Hedge Fund Activity: Q1 2026 in Review
0 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q1 2026, worth a combined $0 — down 100% from $91.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ANEB and 0 opened new positions — a net loss of 18 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was 22NW LP, exiting entirely with an estimated $84.8M sold.
- 0 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q1 2026, down from 19 in Q4 2025.
- Funds reported $0 of Anebulo Pharmaceuticals stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Anebulo Pharmaceuticals positions in Q1 2026 and 18 closed out, a net change of -18 holders.
- The largest Anebulo Pharmaceuticals seller in Q1 2026 was 22NW LP, an estimated $84.8M sold.
Based on aggregated 13F filings for Q1 2026.